Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a EGFR or other growth factor expressed by the cancer and comparing the amount with the amount of EGFR or other growth factor expressed by a reference cancer.
1 . A method of selecting a patient for treatment of a cancer with 10-propargyl-10-deazaminopterin, the method comprising the steps of:
(a) obtaining a sample of the patient's cancer tissue;
(b) determining the expression level of epidermal growth factor receptor (EGFR) expressed in the sample;
(c) comparing the determined expression level in the sample with a reference expression level for EGFR; and
(d) selecting the patient for treatment 10-propargyl-10-deazaminopterin where the comparison of the expression level in the sample of EGFR and the corresponding reference expression level indicate sensitivity of patient's cancer tissue to 10-propargyl-10-deazaminopterin.
2 . The method of claim 1 , wherein the patient's cancer is a solid tumor or a lymphoma.
3 . The method of claim 2 , wherein the solid tumor is selected from the group consisting of NSCLC, head and neck cancer, prostate cancer, and breast cancer.
4 . A method for assessing sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin comprising the steps of:
(a) obtaining a sample of the patient's cancer tissue;
(b) determining the expression level of at EGFR expressed in the sample;
(c) comparing the determined expression level in the sample with a reference expression level for EGFR to determine whether the expression level for EGFR in the sample is indicative of an expression level that predicts sensitivity to 10-propargyl-10-deazaminopterin; and
(d) generating a report of the predicted sensitivity of the sample to 10-propargyl-10-deazaminopterin.
5 . The method of claim 4 , wherein the reference cancer is a solid tumor or a lymphoma.
6 . The method of claim 5 , wherein the solid tumor is selected from the group consisting of NSCLC, head and neck cancer, prostate cancer, and breast cancer.
7 . A method for assessing sensitivity of a cancer to treatment with 10-propargyl-10-deazaminopterin comprising the steps of
(a) obtaining a sample of the lymphoma;
(b) determining the amount of EGFR expressed by the sample wherein higher levels of expressed EGFR are indicative of sensitivity to 10-propargyl-10-deazaminopterin; and
(c) generating a report of the predicted sensitivity of the sample to 10-propargyl-10-deazaminopterin.